NCT02942602

Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Yonsei University · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Accepted

Summary

1\) to test HDL function comprehensively in healthy and diseased individuals; 2) to evaluate if this test correlates with cardiovascular risk, independent of traditional risk factors; 3) and to differentiate effects of lipid-modifying or antiatherosclerotic drugs on HDL function and composition

Conditions

• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	Atorvastatin 20 mg	The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
DRUG	Cholestyramine 8 g	The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
DRUG	Omega-3 2g	The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
DRUG	Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg	The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
BEHAVIORAL	Lifestyle modification	The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.

Timeline

• Start date: 2014-04-03
• Primary completion: 2016-05-23
• Completion: 2016-05-23
• First posted: 2016-10-24
• Last updated: 2018-07-18

Locations

1 site across 1 country: South Korea